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Abstract
NF-kB activation is a critical signaling event in the inflammatory response and has been implicated in a number of
pathological lung diseases. To enable the assessment of NF-kB activity in the lungs, we transfected a luciferase based NF-kB
reporter into the lungs of mice or into Raw264.7 cells in culture. The transfected mice showed specific luciferase expression
in the pulmonary tissues. Using these mouse models, we studied the kinetics of NF-kB activation following exposure to
lipopolysaccharide (LPS). The Raw264.7 cells expressed a dose-dependent increase in luciferase following exposure to LPS
and the NF-kB reporter mice expressed luciferase in the lungs following LPS challenge, establishing that bioluminescence
imaging provides adequate sensitivity for tracking the NF-kB activation pathway. Interventions affecting the NF-kB pathway
are promising clinical therapeutics, thus we further examined the effect of IKK-2 inhibition by MLN120B and glycogen
synthase kinase 3 beta inhibition by TDZD-8 on NF-kB activation. Pre-treatment with either MLN120B or TDZD-8 attenuated
NF-kB activation in the pulmonary tissues, which was accompanied with suppression of pro-inflammatory chemokine MIP-
1ß and induction of anti-inflammatory cytokine IL-10. In summary, we have established an imaging based approach for non-
invasive and longitudinal assessment of NF-kB activation and regulation during acute lung injury. This approach will
potentiate further studies on NF-kB regulation under various inflammatory conditions.
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Introduction
Chronic exposure to significant levels of lipopolysaccharide
(LPS), which is ubiquitously present as a contaminant on airborne
particles [1], is reported to be associated with the development and
progression of many types of lung diseases including asthma and
chronic obstructive pulmonary disease (COPD) [2]. The patho-
genesis of COPD is characterized by pulmonary inflammation
associated with increased accumulation of neutrophils and pro-
inflammatory cytokines in the bronchoalveolar lavage fluid [3]. In
experimental animals, repeated intratracheal LPS instillation
results in persistent chronic pulmonary inflammation with
pathologic changes mimicking certain aspects of clinical COPD
[4].
The NF-kB transcription factor consists of subunits that
associate in dimers [5]. The commonly described dimer forms
are p50 (NF-kB1) with RelA (p65) and p52 (NF-kB2) with RelB.
The NF-kB1/RelA complex remains in the cytoplasm in an
inactive form in association with IkBa. Upon stimulation with LPS
or pro-inflammatory cytokines, IKK2 is activated and causes IkBa
phosphorylation, leading to its ubiquitinization and proteasomal
degradation. This releases the NF-kB1/RelA complex from IkBa
inhibition and allows it to translocate to the nucleus where it
transcriptionally activates many key genes involved in inflamma-
tion and chemotaxis [6–8]. Abnormal NF-kB activation has been
implicated in the pathophysiology of COPD [9], thus NF-kB
pathway blockers, such as MLN120B, are currently being
explored for treatment of inflammatory diseases such as COPD
and asthma [10].
Glycogen synthase kinase (GSK)-3b is a ubiquitous serine-
threonine protein kinase involved in glycogen metabolism [11].
There are two mammalian isoforms of GSK-3, encoded by
different homologous genes, GSK-3a and GSK-3b [12]. GSK-3b
phosphorylates and regulates many substrates, including tran-
scription factors such as b-catenin [13], NF-kB [14], STAT [15]
and other substrates that are critical for metabolism, protein
translation, cell cycle, oncogenesis, and neuroprotection [16-18].
Absence of GSK-3b severely affects the TNF-induced activation of
NF-kB p65 [14] and potentiates TNF-induced apoptosis [19].
Thus, GSK-3b blockers, such as TDZD-8, have therapeutic
potential for treating inflammatory respiratory diseases.
Animal models for assessing NF-kB activity non-invasively have
been of interest for pre-clinical drug development. Luciferase
reporter based animal models that used either short tandem repeat
of NF-kB responsive elements or the promoters of NF-kB
responsive genes have been developed [20–23]. Using several of
these NF-kB reporter mice [20,21], we attempted to image NF-kB
activation in the lungs non-invasively and observed that a systemic
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cheal delivery of LPS. The bioluminescent signal from superficial
tissues interferes with accurate assessment of NF-kB activation in
pulmonary tissues. Due to this limitation, we have explored a
tissue specific gene delivery approach to generate mice with
specific NF-kB-luciferase reporter expression in pulmonary tissues
and validated the utility of non-invasive imaging approaches for
assessing the efficacy of inhibitors of the NF-kB signaling pathway.
Results
In vitro comparison of NF-kB reporters
We transiently transfected three NF-kB reporters into
RAW264.7 cells and monitored their response to LPS treatment.
All three reporters showed induction of luciferase expression after
LPS treatment (Fig 1A). With 1 mg/ml of LPS, the IL8-luc2 and
NF-kB2-luc2 reporters exhibited a 28- and 9-fold induction of
luciferase, respectively, while the TNFAIP3-luc2 reporter showed
a less robust induction of 3-fold under these same conditions
(Fig 1B).
In vivo gene delivery of NF-kB reporters to lung tissues
Incorporation of DNA into cells is influenced by the charge of
the particle, with an overall positive charge required for DNA
entry into cells. Since DNA is negatively charged, the use of JetPEI
is needed to produce a cationic polyethylenimine (PEI)/DNA
complex capable of incorporating into cells in vivo. The N/P ratio
(Nitrogen/Phosphate ratio) of JetPEI used helps to determine the
overall charge of the DNA complex. Complexes are electroneutral
at an N/P ratio of 2–3, and the best transfections are achieved
when using an N/P ratio of 5–8, depending on mouse strain used
and target delivery area. We compared albino C57BL/6 and
BALB/cJ mice in this gene delivery procedure and found that
BALB/cJ mice were more susceptible to mortality than albino
C57BL/6 mice. We observed a survival rate of 79% and 82%
when the N/P ratio of JetPEI was 7 and 6, respectively, using
albino C57BL/6 mice injected with 50 mg of DNA each. When
BALB/cJ mice were used (n=14) with 50 mg of DNA and an N/P
ratio of 7, all mice died within 24 hours. Increased survival (2/2
mice) of BALB/cJ mice was observed when the DNA quantity was
reduced to 25 mg and the N/P ratio reduced to 4.
We used in vivo-JetPEI to deliver the NF-kB reporters to the
lung tissues as described above. Mice were imaged at multiple time
points following DNA delivery (Fig 2A). After 1 day, mice injected
with each of the three NF-kB reporters showed specific
bioluminescence signals in the lungs, which gradually decreased
over time. By 14 days following delivery, the expression decreased
to a low basal level. We used these mice to assess their
responsiveness to LPS treatment. Thus, at two weeks after DNA
delivery, LPS was delivered into these mice intratracheally and
they were imaged 3 hours later (Fig 2A). All three reporters
showed induction of luciferase signal specifically in the lungs
(Fig 2A,B) and the induction was 14.3-, 9.6-, and 6.6-fold for TNF-
AIP3-luc2, NF-kB 2-luc2, and IL8-luc2 transfected mice,
respectively.
Kinetics of NF-kB activation following LPS and TNF-a
challenge
The kinetics of luciferase induction by LPS and TNFa was
studied using TNFAIP3-luc2 transfected mice. LPS (1 mg/kg) was
delivered intratracheally or TNFa was injected intravenously at a
dose of 1 mg/mouse. Both LPS and TNFa induced a specific
signal in the lungs 3 hours after injection (Fig 3A). Quantification
of the lung signal shows that the induction reached a plateau at
3 hours following LPS or TNFa administration and declined at
6 hours. (Fig 3B). We also used TNFa at 0.5 and 2 mg/mouse and
achieved a comparable level of luciferase induction in the lungs
(data not shown). Similarly, LPS at 2 mg/kg induced a similar
level of NF-kB activation as the 1 mg/kg dose (data not shown).
Comparison of anti-inflammatory compounds on NF-kB
induction in vitro
Two anti-inflammatory compounds: MLN120B, an IKK2
inhibitor; and TDZD-8, a GSK-3b inhibitor, were compared for
their effects on LPS induced NF-kB activation. We transiently
transfected the NF-kB reporters into RAW267.4 cells and induced
inflammation in the cells with LPS. The effect of these compounds
Figure 1. In vitro comparison of NF-kB reporters. RAW264.7 cells were transiently transfected with NF-kB reporters. Cells were treated with LPS
at 0–1 mg/ml concentrations overnight and imaged with IVIS after adding luciferin. Quantification of luciferase signal (A). Fold change of cells treated
with 1 mg/ml LPS compared to vehicle treated cells (B). Data presented as mean 6 SEM; n=4 wells per reporter construct and LPS concentration of
1 mg/ml.
doi:10.1371/journal.pone.0025093.g001
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compounds showed an inhibitory effect on LPS induced NF-kB
activation (Fig 4). The IC50 value of MLN120B was 1.4, 14.8 or
27.3 mM for NF-kB2-luc2, IL8-luc2 or TNF-AIP3-luc2 reporter
transfected cells, respectively, indicating that IKK2 inhibition
affected the transcriptional activity of the NF-kB2 promoter most
effectively. Treatment with TDZD-8 resulted in a much more
uniform inhibition of the three NF-kB reporters with IC50 values
for TNF-AIP3-luc2, NF-kB2-luc2, or IL8-luc2 of 4.0, 6.9, or
8.4 mM, respectively.
IKK2 inhibition attenuates NF-kB activation in the lungs
Using NF-kB reporter transfected mice, we tested the effect of
the IKK2 inhibitor, MLN120B, on LPS induced NF-kB activation
in the lungs. This compound failed to show any effect when
TNFAIP3-luc2 transfected mice were used (data not shown). Since
the TNFAIP3 gene is involved in the negative feedback loop of
NF-kB signaling [25], the luciferase signal on the one hand may
represent NF-kB activation, but on the other hand, it may also
reflect the extent of suppression of the NF-kB pathway. Thus, we
focused on NF-kB2-luc2 transfected mice for drug inhibition
studies. Pre-treatment with MLN120B (300 mg/kg orally at 16
and 1 hour prior to challenge) generated suppression of LPS-
induced luciferase expression in the lungs when compared to the
vehicle-control mice 4 hours after LPS challenge. Quantification
of the lung signal showed an approximate 70% inhibition by
MLN120B (Fig 5A,B). After imaging, mice were sacrificed and
BAL fluid was harvested for cytokine analysis. Induction of MIP-
1b, MCP-1, KC, IL-6 and TNFa was observed in BAL from LPS
treated mice (Fig 5C). Significantly decreased levels of the pro-
inflammatory chemokine MIP-1b and increased levels of the anti-
inflammatory cytokine IL-10 were detected in the BAL of
MLN120B pre-treated mice as opposed to LPS-treated positive
controls.
Suppression of NF-kB activation in the lungs by a
glycogen synthase kinase beta TDZD-8
As shown above (Fig 4), TDZD-8 is more potent than
MLN120B in mitigating LPS induced NF-kB activation in
Raw264.7 cells with all three reporters except NF-kB2-luc2. We
examined its effect on NF-kB activation during LPS-induced lung
inflammation in NF-kB2-luc2 transfected mice. Mice treated with
LPS alone exhibited induction of bioluminescence signals in the
lungs as expected. Pre-treatment of mice with 10 mg/kg of
TDZD-8 (i.p.) totally abolished LPS induced signals in the lungs
(Fig 6A, B). In addition, significantly decreased levels of the pro-
inflammatory chemokine MIP-1b and increased levels of the anti-
inflammatory cytokine IL-10 were detected in the BAL of TDZD-
8 pre-treated mice as opposed to LPS-treated positive controls
(Fig 6C).
Discussion
The NF-kB transcription factor family plays a pivotal role in
regulating innate inflammatory response underlying the patho-
genesis of pulmonary diseases [9,10]. We evaluated the utility of
three NF-kB responsive reporters for monitoring NF-kB activa-
tion. When comparing the extent of induction under both in vitro
and in vivo conditions, differences were observed. TNFAIP3-luc2
mediated the most robust luciferase induction in vivo, but showed
the lowest induction in vitro among all three reporters. It is likely
that the responsiveness of these reporters will be tissue and
induction model dependent. Nonetheless, the difficulty of
monitoring NF-kB activation in the lung non-invasively was
Figure 2. In vivo gene delivery of NF-kB reporters to the lung and response to LPS treatment. Albino C57BL/6 mice (n=3 per group)
were injected intravenously with NF-kB reporter DNA using JetPEI. Mice were imaged following i.p. injection of luciferin at 1, 5, 7, and 14 days
following transfection. After the imaging on the day 14, mice were intratracheally challenged with LPS at 1 mg/kg and re-imaged after 3 hours.
Bioluminescence images (A) and quantification of bioluminescence signal from the lungs (B). Quantification was performed by drawing a region of
interest (ROI) over the chest area followed by quantification using the LivingImage software. Data presented as mean 6 SEM.
doi:10.1371/journal.pone.0025093.g002
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intratracheal LPS delivery to demonstrate specific NF-kB
induction in the lungs. Chronic exposure to LPS is reported to
be associated with the development and/or progression of many
types of lung diseases, including asthma, chronic bronchitis, and
progressive irreversible airflow obstruction that are all character-
ized by chronic inflammatory processes in the lung. [4]. Thus our
model will be useful for studying the NF-kB signaling pathway in
these diseases.
Delivery of cationic polyethylenimine (PEI)/DNA complex
caused mortality of the injected animal. It has been reported that
pulmonary delivery of cationic lipid-DNA complexes can induce
acute inflammation and tissue damage due to the presence of
immunostimulatory CpG motifs within the plasmid DNA vector
[24]. Thus, High NF-kB activity at day1 after transfection (Fig 2)
was a manifestation of acute lung inflammation induced by the
delivered DNA. Following the acute response, inflammatory NF-
kB signal in the lungs declined to basal levels by two weeks. Our
study also indicated that cationic PEI/DNA elicited toxicity was
mouse strain dependent. When 50 mg of DNA was injected
intravenously per animal, C57BL/6 albino mice showed an
approximate 80% survival rate whereas none of the BALB/cJ
mice survived. With lower quantities of DNA (25 mg), BALB/cJ
mice exhibited a 100% survival rate (n=2). Gene delivery to the
respiratory system is of clinical interest for treatment of pulmonary
diseases such as lung cancer, cystic fibrosis, and allergen-induced
airway hyper-responsiveness [25]. Bioluminescence imaging is an
ideal approach for evaluating gene delivery efficiency in animal
models due to its superior sensitivity. In this study, we used an
intravenous approach for gene delivery to lung tissues; however,
recent studies demonstrated delivery of luciferase reporters as
inhaled aerosols with sensitive detection of pulmonary luciferase
activity in mice [26,27]. A comparison of different agents and
approaches for gene delivery efficiency will be explored in future
Figure 3. Kinetics of NF-kB activation. TNFAIP3-luc2 reporter
transfected mice were challenged with LPS (1 mg/kg, intratracheally,
n=11) or TNFa (1 mg/mouse, intravenously, n=4) or saline (n=4). Mice
were imaged at 0 (prior to injection), 3, 6, and 24 hours after injection.
Bioluminescent images from one representative mouse per group (A)
and quantification of lung signals (B) are shown. Data presented as
mean 6 SEM.
doi:10.1371/journal.pone.0025093.g003
Figure 4. Effect of anti-inflammatory agents on NF-kB induc-
tion in vitro. The effect of MLN120B (A) and TDZD-8 (B) on luciferase
induction by LPS in TNFAIP3-luc2, NF-kB2-luc2 and IL8-luc2 transfected
RAW264.7 cells are shown. All the compounds were tested at 1–100 mM
concentrations. The data are presented as percentage change over
vehicle treated cells. Data presented as mean 6 SEM; n=4 wells per
reporter construct and LPS concentration.
doi:10.1371/journal.pone.0025093.g004
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clinical application.
Due to the pathophysiological complexity of chronic pulmonary
diseases, efforts have been made to identify anti-inflammatory
drugs that can attenuate the pro-inflammatory process at an early
stage of disease. Hallmarks of the pathophysiology of lung
inflammation are the release of multiple pro-inflammatory
cytokines, reactive oxygen species, and infiltration of neutrophils
into inflamed tissues. The NF-kB pathway plays a pivotal role in
mediating this pathophysiologic development and constitutes a
potential therapeutic strategy for inhibiting the release of
inflammatory mediators. Establishment of imaging based animal
models for tracking NF-kB activation in the lung enables high-
throughput in vivo drug screening. As a proof of concept study, we
tested the effect of two anti-inflammatory compounds on NF-kB
activation in the lung. MLN120B is a potent and selective small
molecule inhibitor of IKK-2, which is a predominant activator of
NF-kB. Suppression of IKK-2 by MLN120B correlates with
inhibition of IkBa phosphorylation and degradation in mouse
tissues after the animals were given a single oral dose of 300 mg/
kg [28]. With the same dose, we demonstrated that MLN120B
significantly attenuated LPS induced NF-kB reporter activation in
the lungs. We observed very little inhibitory effect on LPS induced
NF-kB reporter activation in the lungs when a lower dose of
50 mg/kg MLN120B was used (result not shown). The MLN120B
drug efficacy with different dosages resembles a recent study which
showed that MLN120B had a robust inhibitory effect on arthritis
development when dosed to mice orally twice a day at 60 mg/kg,
but had very little effect at 10 or 30 mg/kg [29].
Involvement of GSK3ß in numerous intra-cellular signaling
pathways underscores its etiological role in a number of diseases,
including diabetes, Alzheimer’s disease, bipolar disorder, and
cancer [16–18]. A recent report showed that in innate immune
cells, GSK3 inactivation augments anti-inflammatory cytokine
production while concurrently suppressing the production of pro-
inflammatory cytokines [30]. Ability of GSK-3ß to affect the NF-
kB signaling pathway has been shown in a number of studies
[31,32]. GSK-3ß protects hepatocytes from TNF-induced
apoptosis through p65 phosphorylation and upregulation of
NF-kB transactivation [31]. In GSK-3ß gene-deleted cells, NF-
kB activation induced by LPS, IL-1ß, or cigarette smoke
condensate was completely suppressed, due to suppression of
IkBa kinase activation and IkBa phosphorylation, ubiquitination,
and degradation [19]. Animal studies have demonstrated that
GSK3 inhibitors can suppress inflammation and protect the host
from inflammation-mediated pathology and death. GSK inhib-
itors are being actively developed as drugs for the treatment of
various disorders [33]. TDZD-8 is a potent selective inhibitor of
GSK-3ß. In vivo studies have demonstrated that inhibition of
GSK-3ß by TDZD-8 reduces the renal and liver dysfunction
caused by both administration of endotoxin and peptidoglycan,
and that this protective effect is due to inhibition of the
phosphorylation of the NF-kB subunit [32]. Inhibition of GSK-
3ß by TDZD-8 also attenuates carrageenan-induced lung injury,
accompanied by suppression of IkBa degradation and P65
phosphorylation [34]. Using our NF-kB2-luc2 transfected mice,
we demonstrated that TDZD-8 significantly suppressed NF-kB
induction by LPS.
Figure 5. Effect of IKK2 inhibition on NF-kB induction in vivo. At 2 weeks after in vivo gene delivery with the NF-kB2-luc2 reporter, mice
(n=7) were pre-treated with MLN120B at 300 mg/kg orally or vehicle control 16 and 1-hour prior to LPS delivery. Mice were imaged immediately
before LPS injection (T=0) and at 4 hours. Bioluminescence images (A) and quantification of lung signals (B) are shown. Cytokines measured in
bronchial lavage fluid as specified (C). Data presented as standard box and whisker plots, *p,0.05, **p,0.01, ***p,0.001 by Mann-Whitney U test.
doi:10.1371/journal.pone.0025093.g005
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was observed in BAL during LPS induced lung inflammation.
These pro-inflammatory cytokines act in concert to propagate
inflammation [35–39] and elicit injury through the release of
reactive oxygen species (ROS) and proteolytic enzymes [40]. The
anti-inflammatory cytokine IL-10, can inhibit LPS-induced pro-
inflammatory cytokines by inhibiting the NF-kB signaling pathway
[41]. Thus, the observed effect of MLN120B and TDZD-8 in our
study may be in part due to up regulation of IL-10. Indeed, in
prior studies, the absence of endogenous IL-10 enhanced
myeloperoxidase mediated oxidative stress and acute lung injury
[35]. Interestingly, only the pro-inflammatory chemokine MIP-1b
was down-regulated by MLN120B and TDZD-8. Prior studies
suggest that of the CC chemokines, MIP-1b plays the most
important role in intrapulmonary recruitment of neutrophils and
in development of lung injury [42]. Collectively, our study shows
that MLN120B and TDZD-8 exert anti-inflammatory effects
associated with suppression of the NF-kB signaling pathway and
the pro-inflammatory chemokine MIP-1b, while inducing the anti-
inflammatory cytokine IL-10.
In summary, our in vivo gene delivery approach for monitoring
NF-kB activation in the pulmonary tissue provides a sensitive
noninvasive readout of inflammation kinetics. A multitude of
activators and inhibitors concertedly regulate the NF-kB signaling
pathway. Despite this complexity, the NF-kB2-luc2 based reporter
system was able to detect a reduction in inflammation when
different activators of this signaling pathway were inhibited. Our
model may facilitate further pre-clinical characterization of new
anti-inflammatory compounds for treating pulmonary diseases. In
addition, targeted delivery of these NF-kB reporters to other
tissues may also be a useful imaging approach for research in many
other disease areas.
Materials and Methods
Reagents
Bacterial lipopolysaccharide (LPS, from Salmonella abortus-equi)
and TDZD-8 were obtained from Sigma-Aldrich Chemical Co.,
(St. Louis, MO). Recombinant TNFa was obtained from R&D
Systems (Minneapolis, MN), Lipofectamine LTX Transfection
Reagent was obtained from Invitrogen, in vivo JetPEI DNA
transfection reagent (Polyplus Transfection) was obtained from
VWR (Brisbane, CA), and MLN120B was obtained from Chiesi
Pharmaceutical (Marma, Italy).
Cell based assay of NF-kB-luc reporters
We obtained NF-kB reporters from Switch Gear Genomics
(Menlo Park, CA). The constructs contain the promoters of
TNFAIP3, NF-kB2 or IL8 driving expression of the firefly
luciferase (luc) reporter. Raw264.7 cells of 70% confluency were
trypsinized and washed with PBS. Subsequently 1–3610
7 cells
were suspended in 4 ml DMEM (without fetal calf serum or
antibiotics). 50 mg of NF-kB -luc reporter DNA was mixed with
50 ml of Plus Reagent and incubated at room temperature for 5
minutes. Next, 100 mL of Lipofectamine LTX was added to the
DNA mix and incubated at room temperature for 30 min. The
Figure 6. Effect of glycogen synthase kinase beta inhibition on NF-kB induction in vivo. NF-kB2-luc2 reporter transfected mice (n=6 per
group) were pre-dosed with either TDZD-8 (10 mg/kg, i.p.), or DMSO vehicle control 16 and 1-hour prior to LPS challenge. Mice were imaged
immediately before LPS injection (T=0) and at 3 hours post injection. Another group of mice was not treated with LPS and served as negative
controls (n=3). Bioluminescence images (A) and quantification of lung signals (B) are shown. Cytokines measured in bronchial lavage fluid as
specified (C). Data presented as standard box and whisker plots, *p,0.05, **p,0.01, ***p,0.001 by Mann-Whitney U test.
doi:10.1371/journal.pone.0025093.g006
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and the mixture was transferred to a T75 flask, followed by 4 hour
incubation at 37uC with shaking. The cells were then plated to a
96 well plate with 150 ml cells/well. Subsequently, 50 mlo f5 X
LPS solution and 50 ml of NF-kB inhibitor solutions (in DMEM
growth media) were added to the plate and the cells were
incubated overnight in a humidified incubator under a 5% CO2
atmosphere. After overnight incubation, the reporter activity was
assayed through imaging with in vivo imaging system (IVISH;
Caliper Life Sciences., Alameda, CA) after adding 20 ml of 30 mg/
ml luciferin to the each well.
In vivo gene delivery
We used in vivo JetPEI (Polyplus Transfection) as a carrier for
delivering DNA to the lung tissues. The DNA and JetPEI were
formulated according to the manufacturer’s instructions with a
final N/P ratio of 7. Briefly, 50 mg of an NF-kB-luc reporter and
7 ml of JetPEI were each diluted into 200 ml with 5% glucose. The
two solutions were then mixed and incubated for 15 minutes at
room temperature. The entire mixture (400 ml) was injected
intravenously into albino C57BL/6 mice and the expression of the
NF-kB reporter was monitored through imaging with an IVISH
imaging system.
In vivo bioluminescence imaging
Mice were anesthetized with isoflurane and imaged for 5
minutes following intraperitoneal injection of 150 mg/kg luciferin.
Imaging was performed with an IVIS Spectrum. Bioluminescent
signals were quantified using Living ImageH software (Caliper Life
Sciences., Alameda, CA.).
Acute pulmonary Inflammation and the effect of anti-
inflammation compounds
LPS was dissolved in sterile PBS to a concentration of 10 mg/
ml. LPS (in 50 ml total volume) was delivered to mice
intratracheally with a 22-gauge intubator. The final dose of LPS
was 1 mg/kg. To perform a dosage study with TNFa, the cytokine
solution was diluted in PBS to concentrations of 0.5, 1, or 2 mgi n
a 100 ml volume and the solutions were delivered to mice
intravenously. Induction of NF-kB reporters was monitored
through imaging with IVIS following i.p. injection of luciferin at
specific time points. To study the effect of anti-inflammatory
compounds, mice were administered with 4-benzyl-2-methyl-
1,2,4-thiadiazolidine-3,5-dione (TDZD-8) (in DMSO, 10 mg/kg,
i.p.), or MLN120B (in 0.5% methylcellulose, 300 mg/kg, p.o.) at
16 hours and 1 hour prior to intratracheal delivery of LPS.
Harvesting bronchoalveolar lavage fluid and cytokine
analysis.
Bronchoalveolar lavage (BAL) was collected as previously
described [38]. Briefly, mouse tracheas were cannulated with an
18-gauge angiocath (Becton Dickinson). The lungs were instilled
with 1 ml of sterile saline 4 times and a total of 3–4 ml lavage fluid
was collected. After centrifugation at 500 g for 10 min, the BAL
fluid was collected and frozen at 280uC until measurement of
interferon (IFN)-c, interleukin (IL)-6, IL-10, tumor necrosis factor
(TNF)a, monocyte chemoattractant protein (MCP)-1, macrophage
inflammatory protein (MIP)-1b, and keratinocyte-derived chemo-
kine/CXCL1 (KC) quantified using the Cytometric Bead Array
Mouse Flex Kit (BD Biosciences; San Jose, CA). The cell pellet
was resuspended in 1 ml of 1% BSA in sterile physiological saline.
Total cell counts were determined using a grid hemocytometer.
Serum was obtained by cardiac puncture. Lungs were harvested
by resection, and tissues were immediately stored in 10% formalin.
Statistical analysis
Significance between two means was calculated using a two-
tailed Mann-Whitney U test. A p value of ,0.05 was considered
significant. Statistical analyses were performed using Prism 5
(GraphPad Software, Inc.; La Jolla, CA).
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